Need for High Radiation Dose (≥70 Gy) in Early Postoperative Irradiation After Radical Prostatectomy: A Single-Institution Analysis of 334 High-Risk, Node-Negative Patients

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 966-974

  Cozzarini, Cesare ^a   Montorsi, Francesco ^a   Fiorino, Claudio ^a   Alongi, Filippo ^a,b   Bolognesi, Angelo ^a   Da Pozzo, Luigi Filippo ^a   Guazzoni, Giorgio ^a   Freschi, Massimo ^a   Roscigno, Marco ^a   Scattoni, Vincenzo ^a   Rigatti, Patrizio ^a   Di Muzio, Nadia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Adjuvant; Dose; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

ADJUVANT; ADJUVANT RADIOTHERAPY; ANDROGEN DEPRIVATION; BIOCHEMICAL RELAPSE-FREE SURVIVAL; CLINICAL OUTCOME; DISEASE-FREE SURVIVAL; HAZARD RATIO; HIGH DOSE; IRRADIATED AREA; MICROMETASTATIC DISEASE; MULTI VARIATE ANALYSIS; NODE-NEGATIVE; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSE; RADICAL PROSTATECTOMY; SIGNIFICANT IMPACTS; UNIVARIATE ANALYSIS;

DECISION MAKING; FLUORINE CONTAINING POLYMERS; MULTIVARIANT ANALYSIS; PEELING; PESTICIDE EFFECTS; RISK ANALYSIS; TUMORS;

RADIOTHERAPY;

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY INTERVENTION; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; LOW ENERGY RADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PELVIS LYMPHADENECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION RESPONSE; SURGICAL APPROACH; THERAPY EFFECT; UROGENITAL TRACT DISEASE; ANALYSIS OF VARIANCE; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; LYMPHADENECTOMY; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY; ROC CURVE; TUMOR RECURRENCE;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 70350781901     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.059     Document Type: Article

References (24)

1. Anscher M.S., Robertson C.N., and Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: Ten-year update. Int J Radiat Oncol Biol Phys 33 (1995) 37-43
2. Schild S.E., Wong W.W., Grado G.L., et al. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 34 (1996) 535-541
3. Syndikus I., Pickles T., Kostashuk E., et al. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol 155 (1996) 1983-1986
4. Petrovich Z., Lieskovsky G., Langholz B., et al. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 600-609
5. Choo R., Hruby G., Hong J., et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: To irradiate or not?. Int J Radiat Oncol Biol Phys 52 (2002) 674-680
6. Cozzarini C., Bolognesi A., Ceresoli G.L., et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: A single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59 (2004) 674-683
7. Vargas C., Kestin L.L., Weed D.W., et al. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61 (2005) 714-724
8. Bolla M., Van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
9. Thompson I.M.J., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296 (2006) 2329-2335
10. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
11. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
12. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
13. Valicenti R.K., Gomella L.G., Ismail M., et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 501-506
14. Valicenti R.K., Gomella L.G., Ismail M., et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: The importance of radiation dose. Urology 52 (1998) 1034-1040
15. Eulau S.M., Tate D.J., Stamey T.A., et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41 (1998) 735-740
16. King C.R., Presti J.C.J., Gill H., et al. Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 59 (2004) 341-347
17. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253
18. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
19. Cox D.R. Regression models and life tables. J Roy Stat Soc 34 (1982) 187-220
20. Gravina G.L., Festuccia C., Galatioto G.P., et al. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology 70 (2007) 728-733
21. Marks L.B., Carroll P.R., Dugan T.C., et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31 (1995) 1257-1280
22. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48 (2000) 369-375
23. Van der Kwast T.H., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25 (2007) 4178-4186
24. King C.R., and Kapp D.S. Radiotherapy after prostatectomy: Is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 71 (2008) 346-350